Severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) infection has caused an increase in mortality and morbidity, but with vaccination, the disease severity has significantly reduced. With the emergence of various variants of concern (VOCs), the vaccine breakthrough infection has also increased. Here we studied circulating spike-specific T follicular response (cTfh) in infection-naïve vaccinees and convalescent vaccinees (individuals who got the Delta breakthrough infection after two doses of BBV152 vaccine) to understand their response as they are the most crucial cells that are involved in vaccine-mediated protection by helping in B-cell maturation. Our results indicated that cTfh cells in both the groups recognized the wild-type and Delta spike protein but memory response to the wild-type spike was superior in infection-naïve than in the convalescent group. The cytokine response, particularly interleukin-21 (IL-21) from cTfh, was also higher in infection-naïve than in convalescent vaccinees, indicating a dampened cTfh response in convalescent vaccinees after breakthrough infection. Also, there was a positive correlation between IL-21 from cTfh cells and neutralizing antibodies of infection-naïve vaccinees. Multiple cytokine analysis also revealed higher inflammation in convalescent vaccinees. Our data indicated that the necessity of a third booster dose may be individual-specific depending on the steady-state functional phenotype of immune cells.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmv.29053DOI Listing

Publication Analysis

Top Keywords

convalescent vaccinees
16
breakthrough infection
12
bbv152 vaccine
8
infection-naïve vaccinees
8
ctfh cells
8
infection-naïve convalescent
8
il-21 ctfh
8
convalescent
6
vaccinees
6
cells
5

Similar Publications

QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis.

Immunol Res

December 2024

Department of Pediatrics, Infectious Diseases and Chemotherapy Research Laboratory, Medical School, National and Kapodistrian University of Athens, Aghia Sophia" Children's Hospital, 11527, Athens, Greece.

A systematic review and meta-analysis were performed to evaluate the virus-specific T-cell response after COVID-19 mRNA vaccination, using the QuantiFERON SARS-CoV-2 interferon-γ release assay. A search was conducted (June 8, 2023) in the PUBMED, SCOPUS, and medRxiv databases, to identify studies reporting the QuantiFERON SARS-CoV-2 (Starter (two antigen tubes) or Starter + Extended Pack (three antigen tubes), cut-off ≥ 0.15 IU/mL) positivity rate (PR) in immunocompetent adults, following the administration of two or three COVID-19 mRNA vaccine doses.

View Article and Find Full Text PDF

Isolation and characterization of spike S2-specific monoclonal antibodies with reactivity to pan-coronaviruses.

Virol Sin

October 2023

College of Basic Medical Sciences, Hengyang Medical School, University of South China & MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China; School of Public Health, University of South China, Hengyang, 421001, China. Electronic address:

• Five broad-spectrum mAbs identified from COVID-19 convalescents and vaccinees possessed the ability to recognize spike S2 of pan-coronaviruses. • Five mAbs targeted distinct but conserved epitopes on spike S2 of pan-coronaviruses. • Three of these five mAbs were competitively bound to the fusion peptide epitopes of coronavirus spike protein.

View Article and Find Full Text PDF
Article Synopsis
  • * The study found that both vaccines had no severe adverse effects and a high percentage of participants showed increased antibody responses after receiving the booster, with 83.3% for Abdala in Phase 1 and 88.6% in Phase 2.
  • * Both vaccines exceeded the immunogenicity goals set by the trial, with significant increases in antibody levels and neutralizing capacity against SARS-CoV-2 variants after the booster dose, indicating strong efficacy.
View Article and Find Full Text PDF

Heterogeneity of SARS-CoV-2 immune responses after the nationwide Omicron wave in China.

Microbiol Spectr

November 2024

Department of Respiratory, Critical Care and Sleep Medicine, School of Medicine, Xiamen University, Xiang'an Hospital of Xiamen University, Xiamen, Fujian, China.

It remains unclear how previous infections and vaccinations influenced and shaped heterogeneous immune responses against Omicron and its variants in diverse populations in China. After the national wave of Omicron in early 2023, we evaluated serum levels of neutralizing antibodies (nAbs) against Omicron (B.1.

View Article and Find Full Text PDF

The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2.

Vaccines (Basel)

April 2024

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Public antibody responses have been found against many infectious agents. Structural convergence of public antibodies is usually determined by immunoglobulin V genes. Recently, a human antibody public class against SARS-CoV-2 was reported, where the D gene (IGHD3-22) encodes a common YYDxxG motif in heavy-chain complementarity-determining region 3 (CDR H3), which determines specificity for the receptor-binding domain (RBD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!